DuPont to buy Mallinckrodt radiopharmacies

Article

DuPont Pharmaceutical’s Canadian subsidiary, DuPont Pharma, has signed letters of intent to purchase two radiopharmacies owned by Mallinckrodt Canada and located in Pointe-Claire, Quebec, and Mississauga, Ontario. In a separate agreement, DuPont

DuPont Pharmaceutical’s Canadian subsidiary, DuPont Pharma, has signed letters of intent to purchase two radiopharmacies owned by Mallinckrodt Canada and located in Pointe-Claire, Quebec, and Mississauga, Ontario. In a separate agreement, DuPont Pharma will gain exclusive distribution rights over the next 10 years for all of Mallinckrodt’s existing nuclear medicine products in Canada.

If finalized, the purchase will expand DuPont’s portfolio to include not only its main product, Cardiolite, which is used for cardiac imaging, but Mallinckrodt’s Octreoscan, for detecting and localizing neuroendocrine tumors; UltraVent, for the diagnosis and localization of gastrointestinal bleeding and cardiac function assessment; and Mag3, for assessment of renal structure and function. The deal is contingent on due diligence review, but DuPont Pharma expects it to be complete by March 1.

Acquiring Mallinckrodt’s radiopharmacies is part of DuPont Pharmaceuticals’ efforts to increase access to nuclear medicine products for physicians and patients across Canada, according to Nicholas Teti, president of the North Billerica, MA-based firm.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.